Degarelix Accord: Uses, Dosage & Side Effects
GnRH Antagonist — Rapidly suppresses testosterone in advanced prostate cancer
Quick Facts About Degarelix Accord
Key Takeaways About Degarelix Accord
- No testosterone flare: Unlike GnRH agonists (such as leuprorelin or goserelin), degarelix immediately suppresses testosterone without causing an initial surge that could worsen cancer symptoms, making it ideal for patients with spinal metastases or urinary obstruction
- Rapid onset of action: Castrate testosterone levels (below 0.5 ng/mL) are achieved within 3 days of the starting dose, compared to 2–4 weeks with GnRH agonists
- Monthly subcutaneous injection: Administered by a healthcare professional as a subcutaneous injection in the abdominal area, with a loading dose of 240 mg (two 120 mg injections) followed by 80 mg monthly
- Injection site reactions are common: About one-third of patients experience pain, redness, or swelling at the injection site, though these are usually mild and resolve within days
- QT prolongation risk: Degarelix may prolong the QT/QTc interval; patients with pre-existing heart conditions or those taking QT-prolonging medications require careful cardiac monitoring
What Is Degarelix Accord and What Is It Used For?
Degarelix Accord is a GnRH (gonadotropin-releasing hormone) receptor antagonist used for androgen deprivation therapy in men with advanced hormone-dependent prostate cancer. It works by competitively blocking GnRH receptors in the anterior pituitary gland, immediately suppressing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn rapidly reduces testosterone production to castrate levels.
Prostate cancer is the second most commonly diagnosed cancer in men worldwide, with approximately 1.4 million new cases annually according to the World Health Organization. The majority of prostate cancers are hormone-dependent, meaning that the cancer cells require androgens — particularly testosterone and its more potent derivative dihydrotestosterone (DHT) — to grow and proliferate. Androgen deprivation therapy (ADT) has been a cornerstone of advanced prostate cancer treatment for over seven decades, since Charles Huggins first demonstrated the androgen dependence of prostate cancer in 1941, a discovery that earned him the Nobel Prize in Physiology or Medicine.
Traditional ADT approaches include surgical castration (bilateral orchiectomy) and medical castration using GnRH agonists such as leuprorelin, goserelin, or triptorelin. While effective, GnRH agonists have a significant clinical limitation: they initially stimulate the GnRH receptors before desensitizing them, causing a transient surge in testosterone levels during the first 1 to 2 weeks of treatment. This phenomenon, known as a "testosterone flare," can lead to a temporary worsening of cancer symptoms, including increased bone pain in patients with skeletal metastases, worsening urinary obstruction, and — in rare but serious cases — spinal cord compression from vertebral metastases. To mitigate this flare, anti-androgens such as bicalutamide are often co-prescribed during the initial weeks of GnRH agonist therapy.
Degarelix was developed to overcome this limitation. As a GnRH receptor antagonist, it binds competitively to GnRH receptors in the anterior pituitary gland, immediately blocking the stimulatory signal that triggers LH and FSH release. This mechanism produces a rapid and sustained suppression of testosterone production without any initial surge. The pivotal CS21 phase III clinical trial demonstrated that degarelix achieved castrate testosterone levels (below 0.5 ng/mL) in 96% of patients within just 3 days of the starting dose, compared to a median of 28 days with the GnRH agonist leuprorelin.
Degarelix Accord is a generic formulation of degarelix, approved by the European Medicines Agency (EMA) as a biosimilar-equivalent generic product. It contains the same active substance as the originator product (Firmagon) and has been shown to be bioequivalent in pharmacokinetic studies. It is indicated for the treatment of advanced hormone-dependent prostate cancer, as well as for the management of patients with prostate cancer where immediate testosterone suppression is clinically necessary.
Degarelix is a synthetic decapeptide that acts as a selective GnRH receptor antagonist. In the hypothalamic-pituitary-gonadal axis, the hypothalamus releases GnRH in pulsatile fashion, which stimulates the anterior pituitary to produce and release LH and FSH. LH then acts on the Leydig cells of the testes to stimulate testosterone production. Degarelix binds competitively to GnRH receptors on pituitary gonadotroph cells, immediately preventing GnRH from activating them. This results in a rapid decrease in LH and FSH secretion, followed by a corresponding fall in serum testosterone levels. Because degarelix blocks the receptor directly without initial activation, there is no testosterone flare — a critical advantage in patients where even a transient rise in testosterone could have serious clinical consequences.
Approved Indications
Degarelix Accord is approved for the following clinical indications:
- Advanced hormone-dependent prostate cancer: For men with locally advanced or metastatic prostate cancer requiring androgen deprivation therapy. Degarelix provides sustained testosterone suppression with monthly maintenance injections.
- Situations requiring immediate testosterone suppression: Particularly suitable for patients at risk of clinical flare, including those with vertebral metastases threatening spinal cord compression, severe lower urinary tract symptoms due to locally advanced disease, or patients who cannot tolerate the initial flare associated with GnRH agonists.
- Neoadjuvant treatment before radiotherapy: Used to downstage or reduce tumor volume before definitive radiation therapy in patients with intermediate- or high-risk localized prostate cancer, where the rapid onset of action is advantageous.
Degarelix vs. GnRH Agonists
The choice between a GnRH antagonist (degarelix) and a GnRH agonist (such as leuprorelin or goserelin) is an important clinical decision that depends on the individual patient's disease characteristics, symptom burden, and cardiovascular risk profile. Several clinical trials and meta-analyses have compared these two approaches:
- Testosterone suppression speed: Degarelix achieves castrate levels within 3 days; GnRH agonists typically require 2–4 weeks and cause a transient flare
- PSA suppression: Post-hoc analyses from the CS21 trial suggest that degarelix may provide more rapid and sustained PSA suppression compared to leuprorelin, though overall survival data are comparable
- Cardiovascular safety: Pooled analyses have suggested that degarelix may be associated with a lower incidence of major cardiovascular events compared to GnRH agonists in patients with pre-existing cardiovascular disease, though this finding requires further prospective validation
- Administration route: Degarelix requires monthly subcutaneous abdominal injections, while some GnRH agonists offer 3- or 6-month depot formulations for less frequent dosing
What Should You Know Before Taking Degarelix Accord?
Before starting degarelix, your doctor will assess your cardiovascular health, liver function, and electrolyte levels. Degarelix is not indicated for use in women or children. Patients with QT prolongation risk factors, severe hepatic impairment, or known hypersensitivity to degarelix or GnRH receptor antagonists should not receive this medication.
Contraindications
Degarelix Accord must not be used in the following circumstances:
- Hypersensitivity: Known allergy to degarelix or any of the excipients in the formulation. Serious hypersensitivity reactions, including anaphylaxis, have been reported rarely with GnRH analogs
- Women and children: Degarelix is not indicated for use in women or pediatric patients. It must not be administered to women who are pregnant or may become pregnant, as it could cause fetal harm through its pharmacological action on reproductive hormones
Warnings and Precautions
Before and during treatment with Degarelix Accord, your healthcare provider should be aware of the following important safety considerations:
- QT/QTc prolongation: Androgen deprivation therapy may prolong the QT interval. Before starting degarelix, your doctor should assess whether the potential benefits outweigh the risks in patients with a history of or risk factors for QT prolongation, including congenital long QT syndrome, those taking Class IA or Class III antiarrhythmic medications, and those with electrolyte abnormalities (particularly hypokalemia or hypomagnesemia). ECG monitoring and correction of electrolyte imbalances should be considered
- Cardiovascular disease: Long-term androgen deprivation therapy is associated with increased cardiovascular risk, including coronary artery disease, myocardial infarction, and cerebrovascular events. Patients with pre-existing cardiovascular conditions should be monitored carefully, and cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, obesity) should be actively managed throughout treatment
- Diabetes and hyperglycemia: ADT can impair glucose tolerance and worsen pre-existing diabetes mellitus. Blood glucose should be monitored regularly, particularly in patients with diabetes or prediabetes, and antidiabetic medications may require adjustment
- Bone mineral density: Long-term testosterone suppression increases the risk of osteoporosis and bone fractures. Baseline and periodic bone density assessments (DEXA scans) should be considered, along with calcium and vitamin D supplementation. Weight-bearing exercise should be encouraged
- Hepatic impairment: Degarelix has not been studied in patients with severe hepatic impairment (Child-Pugh C). Use in these patients is not recommended. Mild to moderate hepatic impairment does not require dose adjustment, but liver function should be monitored
- Renal impairment: Caution is advised in patients with severe renal impairment (creatinine clearance below 30 mL/min), as degarelix has not been extensively studied in this population
Pregnancy and Breastfeeding
Degarelix Accord is not indicated for use in women. There are no data on the use of degarelix in pregnant or breastfeeding women. Based on its pharmacological mechanism of action, degarelix would be expected to cause adverse effects on pregnancy and fetal development. Women of childbearing potential who are partners of men receiving degarelix should be informed of the potential risk, although the drug is administered to the male patient and systemic exposure in a female partner is not expected through normal contact.
Tell your doctor about all medications you are currently taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins. This is particularly important for medications that can affect heart rhythm (QT-prolonging drugs), as the combination with degarelix may increase the risk of serious cardiac arrhythmias. Do not start, stop, or change the dosage of any medicine without your doctor's approval.
How Does Degarelix Accord Interact with Other Drugs?
The most clinically significant drug interactions with degarelix involve medications that can prolong the QT/QTc interval on electrocardiogram. Since androgen deprivation therapy itself may prolong the QT interval, combining degarelix with other QT-prolonging medications can increase the risk of potentially dangerous cardiac arrhythmias, including torsades de pointes.
Degarelix is primarily metabolized through peptide hydrolysis in the hepatobiliary system and is not a significant substrate of cytochrome P450 (CYP) enzymes. This means that degarelix has a relatively low potential for pharmacokinetic drug interactions compared to many other anticancer drugs. However, pharmacodynamic interactions — particularly those related to cardiac electrophysiology — remain an important clinical concern.
In clinical pharmacology studies, degarelix did not show clinically meaningful inhibition or induction of major CYP enzymes, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. This favorable metabolic profile means that degarelix is unlikely to affect the blood levels of co-administered medications that are metabolized through these pathways, and vice versa.
Major Interactions
The following drug combinations with degarelix require particular caution or may be contraindicated:
| Interacting Drug/Class | Risk | Clinical Recommendation |
|---|---|---|
| Class IA antiarrhythmics (quinidine, procainamide, disopyramide) | Additive QT prolongation; risk of torsades de pointes | Avoid combination if possible; if essential, ECG monitoring and electrolyte correction required |
| Class III antiarrhythmics (amiodarone, sotalol, dofetilide) | Additive QT prolongation; high risk of serious arrhythmia | Avoid combination if possible; specialist cardiology input recommended |
| Methadone | QT prolongation; additive cardiac risk | ECG monitoring before and during co-administration; correct electrolyte abnormalities |
| Fluoroquinolones (moxifloxacin, levofloxacin) | QT prolongation potential | Consider alternative antibiotics where possible; monitor ECG if combination is necessary |
| Antipsychotics (haloperidol, chlorpromazine, ziprasidone) | QT prolongation; additive cardiac risk | Risk-benefit assessment; ECG monitoring; use lowest effective antipsychotic dose |
Minor Interactions
The following interactions are generally of lower clinical significance but should still be noted:
- Corticosteroids: Concurrent use of corticosteroids (e.g., dexamethasone, prednisolone) is common in prostate cancer management and does not present a pharmacokinetic interaction with degarelix. However, corticosteroids can independently affect glucose metabolism and bone density, potentially compounding these ADT-related adverse effects
- Bisphosphonates and denosumab: These bone-protective agents are frequently co-prescribed with ADT to prevent osteoporosis and skeletal events. No pharmacokinetic interaction with degarelix is expected, and their co-administration is encouraged when clinically indicated
- 5-alpha-reductase inhibitors: Finasteride and dutasteride may be used concurrently in some clinical scenarios. No significant interaction with degarelix has been identified, though the clinical utility of combining these agents with complete ADT is limited since testosterone levels are already castrate
- Anticoagulants: Warfarin and direct oral anticoagulants (DOACs) do not interact pharmacokinetically with degarelix. However, patients on ADT should have their cardiovascular risk factors carefully monitored, and anticoagulant therapy should be managed according to standard clinical guidelines
What Is the Correct Dosage of Degarelix Accord?
Degarelix Accord is administered as a subcutaneous injection by a healthcare professional. The starting dose is 240 mg (given as two 120 mg injections), followed by a maintenance dose of 80 mg every 28 days (monthly). The injection is given in the abdominal area, and the injection site should be rotated with each administration.
Degarelix Accord must be reconstituted before administration. The powder for injection is supplied in a vial together with a pre-filled syringe containing the solvent (sterile water for injection). The reconstitution must be performed by a healthcare professional following the specific instructions provided with the product to ensure proper dissolution and correct drug concentration. The reconstituted solution should be a clear liquid, free from particles, and should be used immediately after preparation.
Adults
Starting Dose (Month 1)
240 mg administered as two subcutaneous injections of 120 mg each. The two injections should be given in different sites in the abdominal area. This loading dose ensures rapid achievement of castrate testosterone levels.
Maintenance Dose (Month 2 onwards)
80 mg administered as one subcutaneous injection every 28 days (monthly). The injection should be given in the abdominal area, rotating the injection site between administrations. Areas exposed to pressure (e.g., waistband line, belt line) or close to the ribs should be avoided.
| Treatment Phase | Dose | Injections | Frequency |
|---|---|---|---|
| Starting dose | 240 mg total | 2 × 120 mg SC | Once (Day 1) |
| Maintenance | 80 mg | 1 × 80 mg SC | Every 28 days |
Children
Degarelix Accord is not indicated for use in children or adolescents. The safety and efficacy of degarelix in the pediatric population have not been established. Prostate cancer is an adult-onset malignancy, and there is no clinical rationale for the use of this medication in patients under 18 years of age.
Elderly
No dose adjustment is required for elderly patients. The majority of patients enrolled in clinical trials of degarelix were over 65 years of age, and no clinically relevant differences in safety or efficacy were observed between elderly and younger adult patients. However, elderly patients are more likely to have comorbidities such as cardiovascular disease, diabetes, and renal impairment, which should be taken into account during treatment monitoring.
Special Populations
- Hepatic impairment: No dose adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh A or B). Degarelix has not been studied in patients with severe hepatic impairment (Child-Pugh C) and is not recommended in this population
- Renal impairment: No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is advised in patients with severe renal impairment (creatinine clearance <30 mL/min) due to limited clinical data
Missed Dose
If a maintenance injection is delayed, the 80 mg dose should be administered as soon as possible. Treatment should then continue with injections every 28 days from the date of the delayed injection. Missing a dose may lead to a rise in testosterone levels above castrate levels, which could potentially impact treatment efficacy. If a dose is significantly delayed (more than a few days), your doctor may order a testosterone level blood test to confirm that adequate suppression has been maintained or re-established.
Overdose
There is no specific antidote for degarelix overdose. In clinical studies, doses up to 240 mg per injection did not result in additional clinically significant adverse effects beyond those observed at therapeutic doses. In the event of overdose, treatment should be symptomatic and supportive. Since degarelix is administered by healthcare professionals in a clinical setting, the risk of accidental overdose is inherently low. Any suspected overdose should be reported to the treating physician immediately.
Degarelix must be injected subcutaneously (under the skin) in the abdominal area only. It must not be injected intravenously, as this has not been studied and could lead to unpredictable pharmacokinetics and potential adverse reactions. The injection needle should be inserted deeply at an angle of at least 45 degrees into subcutaneous tissue. After injection, a drug depot forms at the injection site, from which degarelix is slowly released over the following month, maintaining therapeutic drug levels and sustained testosterone suppression.
What Are the Side Effects of Degarelix Accord?
The most common side effects of Degarelix Accord are injection site reactions (pain, redness, swelling) and hot flushes. These are expected pharmacological consequences of androgen deprivation. Most side effects are mild to moderate in severity and manageable with appropriate supportive care.
Like all medications, Degarelix Accord can cause side effects, although not everyone experiences them. The side effect profile of degarelix is largely consistent with the class effects of androgen deprivation therapy, with the notable addition of injection site reactions specific to the subcutaneous depot formulation. Understanding these side effects helps patients and healthcare providers work together to manage them effectively while maintaining cancer treatment.
The following side effects have been reported in clinical trials involving over 1,700 patients treated with degarelix. Side effects are categorized according to the frequency convention used by the European Medicines Agency (EMA) and the Council for International Organizations of Medical Sciences (CIOMS):
Very Common
- Injection site reactions: Pain, redness (erythema), swelling, induration (hardening), and nodule formation at the injection site. Reported in approximately 35–40% of patients after the starting dose and less frequently with subsequent maintenance doses. Most reactions are mild (Grade 1) and resolve within 1–3 days
- Hot flushes: A direct consequence of testosterone suppression, affecting 25–30% of patients. May be accompanied by sweating, particularly at night. These are the most common systemic side effect of all forms of ADT
Common
- Weight gain: Typically 2–5 kg over the first year, related to changes in body composition (increased fat mass, decreased lean muscle mass) caused by testosterone deprivation
- Musculoskeletal pain: Including back pain, arthralgia (joint pain), and pain in the extremities
- Fatigue and asthenia: General tiredness and weakness, often related to the hormonal changes induced by ADT
- Elevated liver enzymes: Increases in ALT (alanine aminotransferase) and AST (aspartate aminotransferase), usually mild and transient
- Nausea: Mild gastrointestinal discomfort, typically not requiring treatment discontinuation
- Gynecomastia: Breast tissue enlargement and/or tenderness in men, a recognized effect of androgen deprivation
- Insomnia: Difficulty sleeping, often related to hot flushes and night sweats
- Dizziness: Occasional lightheadedness, particularly in the initial phase of treatment
- Headache: Mild to moderate headaches reported in some patients
- Hyperhidrosis: Excessive sweating, usually accompanying hot flushes
Uncommon
- QT prolongation: Changes in cardiac electrical activity that may increase the risk of arrhythmia
- Atrial fibrillation: Irregular heart rhythm
- Hypertension: Elevated blood pressure
- Mental impairment: Cognitive changes, including difficulty concentrating and memory problems
- Depression and mood changes: Mood disturbances related to hormonal suppression
- Testicular atrophy: Reduction in testicular size, an expected consequence of prolonged LH suppression
- Erectile dysfunction: Loss of sexual function due to testosterone deprivation
- Bone density loss: Reduced bone mineral density with prolonged treatment, increasing fracture risk
Rare
- Anaphylactic reactions: Severe allergic reactions including swelling of face, lips, or throat, difficulty breathing, and severe skin rash. Seek immediate emergency care
- Febrile neutropenia: Very rarely reported; fever with low white blood cell count
- Injection site abscess: Localized infection at the injection site requiring medical attention
It is important to distinguish between side effects that are specific to the degarelix formulation (primarily injection site reactions) and those that are general consequences of androgen deprivation therapy (hot flushes, metabolic changes, bone density loss, sexual dysfunction, mood changes). The latter group of side effects would be expected with any form of ADT, including GnRH agonists and surgical castration.
Contact your healthcare provider or emergency services immediately if you experience any of the following: severe allergic reaction (difficulty breathing, facial swelling, severe rash), chest pain or irregular heartbeat, signs of injection site infection (increasing pain, warmth, redness, pus, or fever), or symptoms of spinal cord compression (new or worsening back pain, leg weakness, or loss of bladder/bowel control).
Long-Term Effects of Androgen Deprivation
Patients receiving long-term ADT with degarelix should be aware of the following metabolic and health consequences that develop over months to years of treatment:
- Metabolic syndrome: ADT increases the risk of insulin resistance, dyslipidemia (abnormal cholesterol levels), central obesity, and metabolic syndrome. Regular monitoring of fasting glucose, HbA1c, and lipid profiles is recommended
- Cardiovascular risk: Emerging evidence suggests that ADT may increase the risk of cardiovascular events, particularly in men with pre-existing cardiovascular disease. Active management of modifiable risk factors (blood pressure, cholesterol, smoking cessation, exercise) is essential
- Osteoporosis and fractures: Testosterone is important for maintaining bone mineral density in men. Prolonged ADT leads to progressive bone loss, increasing the risk of osteoporotic fractures. Baseline and periodic DEXA bone density scans, calcium and vitamin D supplementation, and consideration of bisphosphonate or denosumab therapy are recommended
- Anemia: Testosterone stimulates erythropoiesis (red blood cell production). ADT can lead to mild normocytic anemia, which may contribute to fatigue
- Cognitive changes: Some patients report difficulties with memory, concentration, and cognitive processing during ADT. The relationship between ADT and cognitive decline is an active area of research
How Should You Store Degarelix Accord?
Degarelix Accord should be stored below 25°C (77°F) in the original packaging to protect from light. Do not freeze. The reconstituted solution should be used immediately and must not be stored for later use.
Proper storage of Degarelix Accord is essential to maintain the drug's stability, potency, and safety. As a lyophilized (freeze-dried) powder that requires reconstitution before injection, the storage requirements apply primarily to the unopened product. Since degarelix is administered by healthcare professionals in clinical settings, patients typically do not need to store the medication at home. However, understanding the storage requirements helps ensure that the product you receive has been properly handled.
- Temperature: Store at or below 25°C (77°F). Do not freeze the product, as freezing may alter the physical properties of the lyophilized powder and the solvent, potentially affecting reconstitution and drug release characteristics
- Light protection: Keep the vials in the original outer carton to protect from light. Degarelix is a peptide that may degrade upon prolonged light exposure
- Shelf life: Do not use Degarelix Accord after the expiry date printed on the carton and vial label. The expiry date refers to the last day of that month
- After reconstitution: The reconstituted solution should be used immediately. From a microbiological standpoint, the product should be administered promptly after preparation to avoid the risk of microbial contamination. Do not store reconstituted solution for later use
- Disposal: Any unused product or waste material should be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of medications via household waste or wastewater
If you are prescribed degarelix and need to transport the product to a clinic, keep it in its original packaging and avoid exposing it to extreme temperatures or direct sunlight. If there is any concern about the storage conditions of a specific vial (e.g., it was left in a hot car or exposed to freezing temperatures), it should not be used, and a replacement should be obtained.
What Does Degarelix Accord Contain?
Degarelix Accord contains degarelix (as acetate) as the active substance. Each vial contains 80 mg of degarelix. The solvent is sterile water for injection (0.5% mannitol solution), supplied in a pre-filled syringe.
Active Ingredient
The active ingredient is degarelix, a synthetic linear decapeptide amide that functions as a GnRH receptor antagonist. It has the molecular formula C82H103ClN18O16 and a molecular weight of approximately 1,632 Da. Degarelix is supplied as the acetate salt. Each vial of Degarelix Accord 80 mg contains 80 mg of degarelix (as acetate), which after reconstitution with the supplied solvent yields a solution for subcutaneous injection at a concentration of 20 mg/mL.
Excipients
The product contains the following inactive ingredients:
- Powder vial: Mannitol (E421) — used as a bulking agent and cryoprotectant during the lyophilization process to ensure structural integrity of the freeze-dried cake
- Solvent (pre-filled syringe): Water for injections — sterile, pyrogen-free water used to reconstitute the lyophilized powder into an injectable solution
Degarelix Accord does not contain any preservatives, which is why the reconstituted solution must be used immediately after preparation. The formulation is designed to be simple and well-tolerated, with a minimal number of excipients. After subcutaneous injection, the reconstituted degarelix forms a gel-like depot at the injection site, from which the active substance is slowly released over the following 28 days, providing sustained therapeutic drug levels and continuous testosterone suppression.
Physical Appearance
The powder for injection is a white to off-white lyophilized (freeze-dried) cake or powder. The solvent is a clear, colorless solution. After reconstitution according to the instructions, the resulting solution should be clear and free of visible particles. If the reconstituted solution appears cloudy, contains particles, or has an unusual color, it should not be used.
Frequently Asked Questions
Medical References
All medical information in this article is based on peer-reviewed research, international clinical guidelines, and official drug regulatory documentation. Evidence level: 1A (systematic reviews and meta-analyses of randomized controlled trials).
- European Medicines Agency (EMA). "Degarelix Accord — Summary of Product Characteristics (SmPC)." EMA Official European regulatory documentation for degarelix.
- U.S. Food and Drug Administration (FDA). "FIRMAGON (degarelix for injection) — Prescribing Information." FDA FDA-approved labeling and safety information for degarelix.
- Klotz L, et al. (2008). "The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer." BJU International. 102(11):1531–1538. doi:10.1111/j.1464-410X.2008.08183.x Pivotal CS21 phase III trial comparing degarelix to leuprorelin in prostate cancer.
- Crawford ED, et al. (2011). "A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer." Journal of Urology. 186(3):889–897. doi:10.1016/j.juro.2011.04.083 CS21 extension study showing sustained efficacy and safety of degarelix and crossover data.
- Mottet N, et al. (2024). "EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer." European Urology. EAU Guidelines European Association of Urology comprehensive guidelines on prostate cancer management.
- Albertsen PC, et al. (2014). "Cardiovascular morbidity associated with gonadotropin-releasing hormone agonists and an antagonist." European Urology. 65(3):565–573. doi:10.1016/j.eururo.2013.10.032 Pooled analysis of cardiovascular outcomes comparing degarelix to GnRH agonists.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines — 23rd list." WHO Essential Medicines WHO reference list for essential cancer medications and hormonal therapies.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Medical Editorial Team
Specialists in urology, oncology, and clinical pharmacology
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic backgrounds and clinical experience. Our editorial team includes:
Urology Specialists
Licensed physicians specializing in urology and uro-oncology, with documented experience in advanced prostate cancer treatment and androgen deprivation therapy.
Clinical Pharmacologists
Experts in clinical pharmacology with extensive knowledge of drug interactions, pharmacokinetics, and evidence-based prescribing in oncology.
Researchers
Academic researchers with published peer-reviewed articles on hormone therapy, GnRH receptor pharmacology, and prostate cancer therapeutics.
Medical Review
Independent review panel that verifies all content against international medical guidelines, EAU, NCCN, and current research.
Qualifications and Credentials
- Licensed specialist physicians with international specialist competence
- Documented research background with publications in peer-reviewed journals
- Continuous education according to WHO, EMA, EAU, and international medical guidelines
- Follows the GRADE framework for evidence-based medicine
- No conflicts of interest or pharmaceutical industry funding
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer reviews before publication.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in urology, oncology, pharmacology, internal medicine, and clinical research.